PLoS ONE · 2019 · 32 citations · 20 references
MedicineNeurosciencePharmacologyNeuroimmunologyNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeuroinflammationNeuroprotectionAtypical Antipsychotic TreatmentBlood-brain Barrier PermeabilityClozapine PharmacologyDemyelination ModelsExperimental Autoimmune EncephalomyelitisMultiple Sclerosis ModelsNeuroinflammation In Multiple SclerosisNeuroinflammatory Mechanisms
The atypical antipsychotic agent, clozapine, is used to treat a variety of neurological disorders including schizophrenia and Parkinson's disease and readily crosses the blood brain barrier to interact with a wide range of neuroreceptors including those for dopamine and serotonin. Recent work has shown that clozapine can reduce neuroinflammation in experimental autoimmune encephalomyelitis, a neuroinflammatory model of multiple sclerosis (MS) and mediates its effects in the central nervous system. To further characterise the protection provided by clozapine, the cuprizone model of demyelination was used to assess the effect of clozapine treatment on the cellular events surrounding demyelination and remyelination. Using this model of non-immune demyelination, we found that clozapine administration was unable to prevent demyelination, but when administered post demyelination, was able to enhance the rate of functional recovery. The more rapid improvement of clozapine-treated mice correlated with a decreased level of astrocyte and microglial activation but only modestly enhanced remyelination. Together, these studies highlight the potential of clozapine to support enhanced functional recovery after demyelination, such as that occurring during MS.
20
Th1, Th2 and Th3 cytokine alteration in schizophrenia
Yong‐Ku Kim, Aye-Mu Myint, Bun-Hee Lee et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2004 · 188 citations
Medicine, Immunology, Psychiatry +10
Mamun Al‐Amin, Mir Muhammad Nasir Uddin, Hasan Mahmud Reza · Clinical Psychopharmacology and Neuroscience · 2013 · 159 citations · Full text
Pharmacy, Immunology, Psychiatry +14